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Abstract Possible underlying organic causes of psychi-
atric symptoms can be overlooked in the clinical setting. It
is important to increase awareness amongst psychiatric and
neurological professionals with regard to certain inborn
errors of metabolism as, in some cases, disease-specific
therapies are available that can, for instance, treat under-
lying metabolic causes. The following article describes the
basic pathophysiology, clinical and neurological features,
and available diagnostic procedures of six treatable meta-
bolic diseases that are associated with neuropsychiatric
symptoms: Wilson’s disease, cerebrotendinous xanthoma-
tosis, porphyrias, homocysteinemia, urea cycle disorders,
and Niemann-Pick disease type C (NP-C). NP-C is taken as
a particularly relevant example because, while it is tradi-
tionally considered to be a condition that presents with
severe neurological and systemic manifestations in chil-
dren, an increasing number of patients are being detected
who have the adolescent- or adult-onset form, which is
frequently associated with neuropsychiatric signs. A nota-
ble proportion of adult-onset cases have been reported
where NP-C has mistakenly been diagnosed and treated as a
psychiatric condition, usually based on patients’ initial
presentation with psychotic or schizophrenia-like symp-
toms. Underlying organic causes of psychiatric disorders
such as psychosis should be considered among patients with
atypical symptoms and/or resistance to standard therapy.
Alongside improved frameworks for additional multidisci-
plinary diagnostic work in patients with suspected organic
disease, the development of convenient and affordable
biochemical screening and/or diagnostic methods has
enabled new ways to narrow down differential diagnoses.
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Introduction
Inborn errors of metabolism constitute a subgroup of
genetic conditions for which disease-specific treatments are
increasingly becoming available. Some such conditions
present primarily with psychiatric symptoms, but they can
be overlooked in a psychiatric setting. In order to prevent
diagnostic mistakes an organized framework for screening
should be established. In many cases, research into bio-
chemical methods for screening and diagnosis has led to the
development of easy and affordable diagnostic possibilities
that are not only simple to apply (e.g., based on blood or
urine samples) but which also provide quick results.
Improved awareness of metabolic diseases within a neuro-
psychiatric cohort in combination with simple screening
tools should easily improve the diagnostic outcome and,
therefore, ideally, change the treatment approach.
The following article addresses six treatable inherited
metabolic diseases that can initially present with neuro-
psychiatric symptoms. General pathophysiology, clinical
features, and diagnostic methods are summarized with a
particular focus on neurological and psychiatric manifes-
tations. Treatment approaches capable of changing disease
outcomes and, in some cases, improving prognosis, are
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covered. Niemann-Pick disease type C (NP-C) is taken as a
specific example of an inherited metabolic disease where
patients can present initially with isolated psychiatric
symptoms over many years before other symptoms occur,
and where symptoms can be misdiagnosed as schizophre-
nia or other psychiatric diseases, based on the widely used
international systems for the classification of psychiatric
diseases.
In order to enhance diagnostic outcomes, a potential
clinical diagnostic algorithm is proposed that could serve
as an aid to detecting possible cases of organic psychosis
(e.g. as seen in adult-onset NP-C).
Wilson’s disease
Wilson’s disease (WD) is an autosomal recessive disease
that belongs to the group of inherited liver diseases. The
incidence in newborns is estimated to be 1:30,000. WD
typically includes liver disease that appears in the second
decade of life and which is followed by neurological and
psychiatric disorders in the third decade [5, 6, 30].
Genetics and pathogenesis
WD is caused by mutations in the gene encoding ATP7B
Cu translocase, which functions as a copper-transporting
P-type ATPase that regulates levels of copper in the liver.
This enzyme is mainly expressed by hepatocytes and
modulates the synthesis of ceruloplasmin. ATP7B Cu
translocase is mainly located in the canalicular membrane
and helps to excrete copper via bile. In WD, the activity of
ATP7B is impaired at the membrane level. Consequently
copper accumulates within the hepatocyte. Copper in its
free ionic form has a relevant redox potential and induces
oxidative stress, attacking cell membranes, proteins, and
DNA, particularly in the liver and brain. Generally, the
brain is affected symmetrically with excess copper depo-
sition, although symptoms can be worse on one side of the
body than another. The copper is often seen most promi-
nently in the basal ganglia [6].
Clinical features
Psychiatric manifestations
Psychiatric features include emotional lability, impulsive-
ness, disinhibition, and self-injurious behavior. The repor-
ted percentage of patients with psychiatric symptoms as the
presenting clinical feature is 10–20 %. Psychiatric abnor-
malities associated with WD have been divided into
behavioral, affective, schizophrenia-like, and cognitive. Cog-
nitive impairment is generally mild [1]. Schizophreniform
disorders, catatonia, and hallucinations are no more com-
mon in WD than in the general population, but psychosis
and catatonia occur more commonly in neurological WD
[1]. Patients with WD having predominantly neuropsychi-
atric symptoms, present with symptoms later in life, have a
longer time delay from onset of symptoms until definitive
diagnosis, and have a poorer outcome compared with
patients with hepatic symptoms [8].
Neurological manifestations
The most common presenting neurologic feature is asym-
metrical tremor, occurring in approximately half of
patients. Frequent early symptoms include difficulty
speaking, excessive salivation, ataxia, mask-like faces,
clumsiness with the hands, and personality changes. Late
manifestations include dystonia, spasticity, grand mal sei-
zures, rigidity, and flexion contractures [6].
Eye manifestations
A Kayser-Fleischer (K-F) ring is a golden to greenish-
brown annular deposition of copper located in the periphery
of the cornea. Approximately 95 % of WD patients pre-
senting with neurological signs will have a K-F ring,
compared with a relatively smaller proportion (approxi-
mately 65 %) of patients who present with hepatic signs [6].
Liver manifestations
Liver disease in WD patients is highly variable, ranging
from asymptomatic cases with mild hepatomegaly and
slight increases in serum hepatocellular enzymes, to
chronic liver disease with severe steatosis, up to fibrosis,
cirrhosis, and severe liver failure. In approximately two-
thirds of cases there is hemolytic anemia, coagulopathy,
and/or renal failure [6].
Diagnosis
The diagnosis of WD is achieved using relatively simple
tests that can be applied in symptomatic patients as well as
people who show no signs of the disease. These tests include
ophthalmologic slit-lamp examination for K-F rings, serum
ceruloplasmin test, 24-h urine copper test, liver biopsy for
histology and histochemistry and copper quantification, and
genetic testing [5, 6, 30]. In symptomatic cases the ‘face of
the miniature panda’ is seen within the pontine tegmentum;
it is delineated by the relative hypointensity of the medial
longitudinal fasciculi and central tegmental tracts in contrast
with the hyperintensity of the aqueduct opening into the
fourth ventricle bounded inferiorly by the superior medul-
lary velum and superior cerebellar peduncles [36].
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Treatment
With proper therapy, disease progress can be halted and
symptoms can be improved [6]. Treatment is aimed at
removing excess accumulated copper and preventing its re-
accumulation. Chelation therapy drugs approved for treat-
ing WD include penicillamine (with maintenance dose
750–1,000 mg/day administered in two divided doses) and
trientine (750 or 1,000 mg used for maintenance in two or
three divided doses [47]). Both of these drugs act by che-
lation or binding of copper, causing its increased urinary
excretion. Metallothionein inducer drugs are also approved
for treating WD. Zinc acts by blocking the absorption of
copper in the intestinal tract. This action both depletes
accumulated copper and prevents its re-accumulation.
Patients with severe hepatitis or liver failure may require a
liver transplant [6]. Little is known about treating psychi-
atric conditions in WD. Clinical improvement in WD with
treatment is generally limited to the first 5 years of
symptoms [1]. Early recognition and treatment are, there-
fore, essential.
Cerebrotendinous xanthomatosis
Cerebrotendinous xanthomatosis (CTX) is a lipid storage
disease characterized by infantile-onset diarrhea, child-
hood-onset cataract, adolescent- to young adult-onset ten-
don xanthomas, and adult-onset progressive neurological
dysfunction and psychiatric disturbances [27, 28].
Genetics and pathogenesis
CTX is caused by deficiency of the mitochondrial enzyme,
sterol 27-hydroxylase, which results in cholestanol and
cholesterol accumulation in virtually every tissue.
CYP27A1 is the only gene in which mutations are known to
cause CTX. The condition is inherited in an autosomal
recessive manner [14, 27, 28].
Clinical features
Neuropsychiatric signs
Intellectual disabilities occur in the early twenties in more
than 50 % of individuals. Neuropsychiatric symptoms such
as behavioral changes, hallucinations, agitation, aggres-
sion, depression, and suicidal attempts may be prominent
[27]. Behavioral/personality disorder is the most frequent
psychiatric manifestation in all age groups, but especially
so in patients younger than 26 years, followed by mood/
affective disorder [27]. In patients older than 26 years,
psychiatric pathology is more complex, with richer
semeiology often in the context of pre-dementia/dementia
[13].
Neurological signs
Pyramidal signs and/or cerebellar signs become evident at
20–30 years of age [27].
Gastrointestinal signs
Chronic diarrhea from infancy may be the earliest clinical
manifestation [28].
Eye signs
In approximately 75 % of the affected individuals, cata-
racts are the first finding, usually in the first decade of life
[28].
Skin signs
Xanthomas associated with the Achilles tendon, the
extensor tendons of the elbow and hand, the patellar tendon
and the neck tendons appear in the second or third decade
of life [28].
Diagnosis
When clinical signs are evident, CTX is diagnosed by
biochemical testing. High plasma and tissue concentrations
of cholestanol confirm the diagnosis.
Treatment
Long-term treatment with chenodeoxycholic acid (CDCA;
average dosage 300 mg/day) improves neurophysiological
findings [23]. Cataract extraction is usually required. Epi-
lepsy, spasticity, parkinsonism, and psychiatric symptoms
are treated symptomatically [28].
Porphyrias
The porphyrias are inherited metabolic disorders of heme
biosynthesis in which specific patterns of heme precursor
overproduction are associated with characteristic clinical
features. Each type of porphyria is the result of a specific
impairment of the activity of one of the enzymes involved
in heme biosynthesis. Porphyrias are classified as erythro-
poietic or hepatic in type, depending on the primary organ
in which excess production of porphyrins or their precur-
sors takes place [16].
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Genetics and pathogenesis
The porphyrias are inherited by a dominant autosomal
mechanism, except in the cases of congenital erythropoietic
porphyria (CEP) and delta-aminolevulinic acid dehydratase
(ALAD) deficiency, which are inherited by a recessive
autosomal mechanism. Not all gene carriers of inherited
porphyrias develop clinical disease, and there is a significant
interplay between the primary gene defect and the secondary
acquired or environmental factors (e.g., medication, liver
damage, hormonal changes and starvation) [16].
Heme pathway intermediates are potentially toxic. Their
overproduction causes the characteristic neurovisceral and/
or photosensitizing symptoms. Porphyrins produce free
radicals when exposed to ultraviolet light. As a result, skin
damage ensues in light-exposed areas resulting in cutaneous
porphyrias. In contrast to porphyrins, their precursors are
associated with neurological symptoms or acute hepatic
porphyrias. Porphyrins and their precursors are excreted in
urine or stool depending on their solubility. Accordingly, the
water-soluble uroporphyrin is excreted in urine, while the
water-insoluble protoporphyrin is excreted via bile and stool.
Coproporphyrin is excreted into both urine and stool because
of its intermediate solubility. Porphyrin precursors are
essentially all excreted in urine. During an acute attack of
porphyria an increased production of heme precursors leads
to the accumulation of porphyrin intermediates [7, 16].
Clinical features
Erythropoietic porphyrias
Porphyrins in red blood cells can cause photosensitive cell
lysis, resulting in hemolytic anemia. The two homozygous
erythropoietic porphyrias, CEP and hepato-erythropoietic
porphyria (HEP), are associated with hemolytic anemia of
varying degrees. In contrast, erythropoietic protoporphyria
(EPP), a heterozygous disease, rarely has accompanying
hemolytic anemia. The effect of life-long anemia in CEP or
HEP may lead to compensatory expansion of erythroid
marrow, which may result in pathological fractures, ver-
tebral compression or collapse, and shortness of stature.
The hemolysis is also associated with varying degrees of
splenomegaly and the production of pigment-laden
gallstones.
Acute hepatic porphyrias
The most common neurovisceral complaints in acute
hepatic porphyrias are abdominal pain, vomiting, consti-
pation, muscle weakness, mental symptoms, head/neck/
chest pain, hypertension, tachycardia, convulsions, sensory
loss, fever, respiratory paralysis, and diarrhea [16].
Chronic hepatic porphyria
Patients with chronic hepatic porphyria, such as Porphyria
cutanea tarda (PCT), are associated with significant chronic
cutaneous photosensitivity but they do not accompany
neurological symptoms. Petechiae and purpuric lesions
may occur. Skin lichenification, leathery pseudovesicles,
and nail changes can be pronounced. Chronic blistering
lesions may develop; the fluid-filled vesicles rupture easily
and the denuded areas become crusted and heal slowly;
secondary infection is common. Previous areas of blisters
may appear atrophic, or brownish. Facial hypertrichosis,
scarring, and hyperpigmentation can also occur [7, 38].
Psychiatric symptoms
Psychiatric symptoms in porphyria have led to controver-
sial discussion [16]. In the past, reported psychiatric
manifestations have included hysteria, anxiety, depression,
phobias, psychosis, organic disorders, agitation, delirium,
and altered consciousness ranging from somnolence to
coma. Some patients were described with psychosis similar
to schizophrenia [3]. Psychiatric manifestations may be
divided into two groups. First, an association between
chronic porphyria and mild anxiety and depression has
been postulated [4]; the nature of this association is yet to
be explained. Second, during the active phase of the acute
attack, clinically obvious psychiatric symptoms such as
psychosis, anxiety, depression, agitation, and delirium are
common and may be present in up to 30 % of patients [10,
15, 34]. The cause of these manifestations is almost cer-
tainly multifactorial and may include common effects of
medication used in the management of the acute attack,
such as sedation and disorientation arising from the use of
opioids, and the effects of metabolic disturbances associ-
ated with the attack (e.g., hypernatremia). Acute psychotic
manifestations such as paranoia and hallucinations can
occur but are very uncommon [16].
Diagnosis
The diagnosis of an acute attack of porphyria requires the
demonstration of increased urinary excretion of the heme
precursor, porphobilinogen (PBG). Molecular diagnostic
testing is powerful and useful in kindred evaluation and
genetic counseling when a disease-causing mutation has
been identified in the family. It is also the only proper way
to screen asymptomatic gene carriers [9, 40].
Treatment
Recognition and avoidance of precipitating events is a key
initial part of treatment. Acute attacks of hepatic
S562 J Neurol (2014) 261 (Suppl 2):S559–S568
123
porphyrias should be treated by providing sufficient
amounts of carbohydrate-derived calories (e.g., by glucose
infusion), and intravenous infusion of hematin [34].
Hemolytic anemia in erythropoietic porphyrias may be
treated by blood transfusion. Cutaneous photosensitivity of
erythropoietic protoporphyria may be treated using oral
b-carotene, while photosensitivity associated with PCT can
be treated by phlebotomy or oral chloroquine. Liver
transplantation can be temporarily beneficial, but trans-
planted livers are susceptible to protoporphyrin-induced
damage [9, 16, 40]. Avoiding precipitating factors such as
the use of illicit drugs, excessive alcohol consumption,
smoking, and severe calorie restriction can help to prevent
attacks. Additionally the maintenance of a regular, bal-
anced diet, prompt treatment of infections, and reduction of
stress can further reduce attacks [49].
Homocysteinemia
High levels of homocysteine are associated with cerebro-
vascular disease, decreased levels of monoamine neuro-
transmitters, and depression of mood.
Genetics and pathogenesis
Homocysteine is a sulfurated amino acid derived from
ingested methionine found in cheeses, eggs, fish, meat, and
poultry. It is directly toxic to neurons and blood vessels and
can induce DNA strand breakage, oxidative stress, and
apoptosis. The pathway produces methyl groups required
for the synthesis of catecholamines and DNA. This is
accomplished by remethylating homocysteine—using
vitamin B12 and folate as cofactors—back to methionine.
Homocysteine is cleared by transulfuration to cysteine and
glutathione, an important antioxidant. Transulfuration
requires vitamins B6 and B12.
The components of the homocysteine-methionine cycle,
as well as cysteine and glutathione and the enzymes of the
pathway, are affected by genetic variation, diet, kidney and
gastrointestinal diseases, and prescribed and over-the-
counter drugs. Since homocysteine is a sensitive indicator
of B vitamin deficiency, an elevated homocysteine level is
a marker for a pathogenic process as well as for a cause of
pathology. Serum levels of homocysteine increase after
methionine loading; in dietary deficiency of vitamin B12,
folate, and vitamin B6 and because of renal disease and
genetic variation of the enzymes essential for the metab-
olism of homocysteine (e.g., methyl-tetrahydro-folate
reductase [MTHFR] and cystathionine beta-synthase
[CBS]). Other causes of hyperhomocysteinemia include
gastric atrophy, inflammatory bowel disease, and laxative
use.
Severe hyperhomocysteinemia predisposes patients to
complications of arterial and venous vascular disease,
with approximately 50 % of patients developing stroke,
myocardial infarction, or pulmonary embolism before
30 years of age [32]. The age at onset and severity of




Moderate hyperhomocysteinemia has also been associated
with an increased risk of the development of dementia. An
association with vascular dementia seems obvious. How-
ever, some studies have suggested that Alzheimer disease,
in particular, is associated with hyperhomocysteinemia.
There is evidence for the association between homocyste-
ine levels and depression, vascular disease, and neuro-
transmitters [35].
Vascular abnormalities
Moderate hyperhomocysteinemia is a risk factor for stroke,
peripheral vascular disease, myocardial infarction, and
venous thromboembolism [32].
Ocular abnormalities
Mild hyperhomocysteinemia is established as an indepen-
dent risk factor for atherothrombotic disease, including
ocular pathologies such as retinal vascular occlusion and
non-arteritic ischemic optic neuropathy (54).
Skeletal abnormalities
Hyperhomocysteinemia can impair the parasympathetic
and sympathetic regulation in the blood vessels of skeletal
muscle and affect long-term muscle function [46].
Diagnosis
A neonatal screening test, called the Guthrie test, detects
high levels of methionine in heel-stick blood. Quantitative
tests for homocysteine in urine and blood are also available.
Measurement of CBS activity in cultured fibroblasts pro-
vides definitive support for the diagnosis. The risk for vas-
cular disease is graded with respect to the level of
homocysteine; however, there is no generally accepted
abnormal threshold value. If homocysteinemia is determined
by a test, then tests for deficiency in folic acid, vitamin B12,
and pyridoxine may also be performed. Genetic abnormali-
ties are reported on chromosome 1 pertaining to MTHFR.
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However, the mere presence of this abnormality may not
confer a risk for vascular disease [12, 35].
Treatment
Hyperhomocysteinemia can be treated directly with vita-
min supplementation. The primary vitamin used to lower
homocysteine levels is folate. A trial of homocysteine
therapy and stroke risk, which randomized 5,522 adults
with known cardiovascular disease to a daily treatment
regimen of B-vitamin therapy (2.5 mg of folic acid, 50 mg
of vitamin B6, and 1 mg of vitamin B12) for 5 years,
achieved a 25 % reduction in the risk of stroke [39].
Enzyme-inducers of cytochrome P450 like carbamaze-
pine or phenytoin should be avoided since they lead to an
increased homocystein level. In cases where antiepileptics
are needed, switching to non-inducing drugs like leveti-
racetam or lamotrigine can be helpful [26].
Urea cycle disorders
Urea cycle disorders (UCD) result from defects in the
metabolism of waste nitrogen from the breakdown of
protein and other nitrogen-containing molecules. The
severity of the urea cycle defect is influenced by the
position of the defective enzyme in the nitrogen metabolic
pathway and the severity of the enzyme defect [24].
Hereditary UCD may present at any age, with a prevalence
of 1:10,000. In addition to forms that present in the neo-
natal period and in young children, there are forms that
manifest later, during adolescence or early adulthood.
Genetics and pathophysiology
Deficiencies are mainly inherited in an autosomal recessive
manner. Severe deficiency results in the accumulation of
ammonia and other precursor metabolites during the first
few days of life.
Clinical features
Psychiatric manifestations
These diseases may be associated with confusion, behav-
ioral disorders or hallucinations suggestive of an atypical
form of depression [2, 36], an acute psychotic disorder, or
even resembling schizophrenia [11]. The psychiatric
symptoms that occur are nearly always accompanied by
headache and/or gastrointestinal symptoms (nausea, vom-
iting). UCD may present initially with postpartum psy-
chiatric symptoms and may represent an under-recognized
cause of postpartum psychosis [11].
Other clinical symptoms
Infants with a severe UCD are normal at birth but rapidly
develop cerebral edema and the related signs of lethargy,
anorexia, hyper- or hypo-ventilation, hypothermia, sei-
zures, neurologic posturing, and coma. In milder (or par-
tial) deficiencies ammonia accumulation may be triggered
by illness or stress at almost any time of life. In these
disorders the elevations of plasma ammonia concentration
and symptoms are often subtle and the first recognized
clinical episode may not occur for months or decades [24].
Patients often have protein intolerance and those with later-
onset disease often spontaneously change their diet,
becoming vegetarians or anorexic [36].
Diagnosis
The diagnosis of a UCD is based on clinical suspicion
as well as biochemical and molecular genetic testing.
Carrier testing for at-risk relatives and prenatal testing
for pregnancies at increased risk using molecular genetic
testing are possible for any of the UCDs if the disease-
causing mutation(s) in the family are known. A plasma
ammonia concentration of 150 lmol/L or higher, asso-
ciated with a normal anion gap and a normal plasma
glucose concentration, is an indication for the presence
of a UCD. Molecular genetic testing is possible for all
UCDs [24].
Treatment
In acute severe hyperammonemia, dialysis and hemofil-
tration are necessary to reduce plasma ammonia concen-
tration. Additionally, intravenous administration of
arginine hydrochloride and nitrogen scavenger drugs
allows alternative pathway excretion of excess nitrogen.
Other treatment strategies include restriction of protein for
12–24 h to reduce dietary nitrogen intake; supply of dietary
calories as carbohydrates and fat, and physiological sta-
bilization with intravenous fluids and cardiac pressors,
while avoiding over-hydration.
Long-term management involves the prevention of
catabolism to avoid hyperammonemic episodes using die-
tary protein restriction, specialized formulas, and oral
nitrogen-scavenging drugs. In order to prevent secondary
complications, it is useful to minimize the risk of respira-
tory and gastrointestinal illnesses by routine immuniza-
tions; multivitamin and fluoride supplementation, and the
appropriate use of antipyretics. Agents such as valproic
acid, prolonged fasting or starvation, intravenous steroids,
and large boluses of protein or amino acids should be
avoided [24].
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Niemann Pick disease type C
Niemann Pick disease type C (NP-C) serves as a good
example of a treatable metabolic disease with psychiatric
symptoms, and with a representative diagnostic work up
for the re-evaluation of initial psychiatric diagnoses.
Genetics and pathogenesis
The underlying genetic and biochemical causes of this
disease have been revised in detail elsewhere [45] and in
this supplement (see [25]).
Clinical features
Psychiatric signs
Special attention should be paid with regard to NP-C in
patients with adolescent- or adult-onset of neurological
symptoms. In comparison to patients with childhood onset,
disease progression among patients with later-onset disease
is less aggressive [31, 52]. Psychiatric symptoms may
dominate the initial clinical impression. Decades can pass
before any neurological manifestations become obvious
and lead to a reconsideration of possible initial psychiatric
diagnosis [44].
In the psychiatric setting, the awareness of organic
causes of psychiatric symptoms may be lacking, particu-
larly with regard to possible associated rare diseases. Even
though physical examination and brain imaging are part of
the diagnostic work up, a necessary re-evaluation of
patients’ status may not be repeated often enough over
time. The clinical picture may change and neurological
deficits that were absent at first presentation may emerge as
the disease progresses [18]. In addition, some movement
disorders and cognitive deficits may be misinterpreted as
part of the possible side effects of long-term medications
used in psychiatric cases [20]. Also the differentiation of
cognitive decline between, for instance, a depressed or
psychotic patient and a patient with an organic disease can
be challenging. Psychological test batteries can provide
some details regarding the nature of cognitive or psychi-
atric deficits, but distinct proof is often still missing [21].
Hence there is a significant need for easily accessible
screening methods for adolescent and adult-onset NP-C. In
addition, follow-up physical examinations and brain
imaging studies are essential.
Psychiatric symptoms associated with NP-C vary
widely [18, 31, 42, 45]. Case studies of adolescent/adult-
onset NP-C have reported the occurrence of psychiatric
symptoms decades before the patient has been admitted to
a neurology department [18, 20, 44]. Patients with ado-
lescent-onset disease primarily show learning disabilities
and/or behavioral problems [17, 31, 45]. Among adult-
onset patients affective disorders, psychosis and cognitive
decline are most often recorded and result in social isola-
tion and performance decline at work and in daily routine
activities [18, 31, 45].
Patients exhibiting psychosis can show a visual hallu-
cinatory phenotype, although other hallucinatory forms
have been described [47]. In one case initial presentation of
the disorder was at the age of 21, with cognitive decline,
perseverations, thought disorders, and incongruity of
affect. At that time the patient was diagnosed with hebe-
phrenic schizophrenia. Six years later he presented with
supranuclear vertical gaze palsy, saccadic eye movements,
bradykinesia, dysarthria, and ataxia, which finally led to the
diagnosis of NP-C [29]. In another case report an 8-year-
old NP-C patient was described with auditory hallucina-
tions and 7 years later developed a typical paranoid
schizophrenic illness that was only partially responsive to
risperidone [37].
Treatment resistance to psychiatric medication (e.g.,
with antipsychotics) is another indicator of possible
organic psychosis related to NP-C. Difficulty in classify-
ing presenting psychiatric symptoms to a known psychi-
atric disease can provide a further clue as to a possible
organic cause for psychosis. In such cases, the necessary
diagnostic criteria are often not fulfilled, leading to con-
fusion and arrival at a number of different diagnoses over
time.
Neuropsychological findings
Cognitive decline features in almost all cases of adolescent
and adult-onset NP-C and generally fulfills criteria for
dementia as the disease progresses, often starting with
difficulties in word fluidity and executive dysfunction [31,
41, 45]. Sleep disturbance can occur [48].
Diagnosis and disease management: a psychiatric
perspective
Processes for screening, diagnosis, and treatment of NP-C
are covered in detail elsewhere [31, 45, 51] and in this
supplement (see [25] [43]). However, from a psychiatric
perspective, no general psychopathological profile has been
proposed to date that describes neuropsychiatric symptoms
in NP-C. However, based on reported findings, a patient
with cognitive dysfunction, missing clear psychiatric
diagnostic criteria, and therapy resistance should be re-
evaluated and diagnostic work up should be repeated to
rule out NP-C as a possible cause. A second, specialist
opinion can be helpful in this respect. Further, brain
imaging can reveal general brain atrophy, although this
may only be seen in the later stages of NP-C. Data indicate
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that, in cases where there is a high suspicion of NP-C,
plasma oxysterol testing can also be useful [19, 33].
Special attention should be paid in cases where there is a
suspected diagnosis of ‘hebephrenic schizophrenia’ (also
called ‘disorganized schizophrenia’). The suggested diag-
nostic criteria for this form of schizophrenia in the World
Health Organization (WHO) ICD-10 diagnostic criteria
include changes in affect, drive, and thought disorders [50].
All of the described symptoms may occur in patients with
NP-C or another metabolic disease with psychiatric
symptoms, as described in the sections above (e.g., meta-
chromatic leukodystrophy [22]). The diagnosis of disor-
ganized schizophrenia itself should lead to a repeated
diagnostic work up, particularly in view of renewed recent
discussions regarding the existence of hebephrenic
schizophrenia.
Conclusion
A number of inherited metabolic diseases have been
described that can initially present with psychiatric signs
and symptoms. Intensive research efforts over the past
three decades have succeeded in defining disease-specific
treatment strategies in a limited proportion of these dis-
eases. Increased awareness of possible underlying causes
of organic psychiatric disorders is required to expedite
revised diagnoses and to allow the appropriate application
of these available therapies. A proposed algorithm for
patients with a number of relevant treatable inherited
metabolic conditions is included in Fig. 1. In particular,
organic causes of psychosis should be considered among
patients with atypical psychiatric symptoms and/or resis-
tance to standard therapy. After further diagnostic pro-
cesses, easy-to-apply screening tests are now available that
can assist in confirming diagnoses.
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Fig. 1 Proposed algorithm defining indicative diagnostic tests for
patients with possible treatable causes of organic psychiatric disease.
CTX Cerebrotendinous xanthomatosis; K-F Kayser-Fleischer (ring);
LTx liver transplantation; NP-C Niemann-Pick disease type C, UCD
urea cycle disorders, VSGP vertical supranuclear gaze palsy, WD
Wilson’s disease
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